Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617849 | 0.90 | USP2 (0.45) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL31500356 | 0.82 | USP2 (0.34) | USP2SMN1; SMN2RECQL | |
| SCHEMBL17190805 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL1978328 | 0.75 | USP2 (0.40) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL1979622 | 0.75 | USP2 (0.40) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL1983350 | 0.75 | USP2 (0.40) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL17113045 | 0.73 | USP2 (0.36) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL1978663 | 0.70 | USP2 (0.39) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL2980172 | 0.70 | USP2 (0.39) | USP2SMN1; SMN2RECQLCTSKHSD11B1 | |
| SCHEMBL2904445 | 0.70 | USP2 (0.39) | USP2SMN1; SMN2RECQLCTSKHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300012-A | Method for preparing 2-methoxy ethylamine hydrochloride | 上海睿瓦科技有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-122059906-A | Compounds for inhibiting PTPN proteins and uses thereof | 艾斯拓康生物医药(天津)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122010871-A | Compounds for inhibiting PTPN proteins and uses thereof | 艾斯拓康生物医药(天津)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| CN-121537623-A | Synthesis method of single molecular weight amino tert-butyloxycarbonyl polyethylene glycol derivative | 武汉软件工程职业学院(武汉开放大学) | 2026-02-17 | — | — | CN | disclosed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-1325008-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| WO-2002010169-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | disclosed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | USP2 2985/4885SMN1; SMN2 238/4885RECQL 531/4885 |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | GPR119, GIPR, INMT | USP2 2439/4885SMN1; SMN2 1512/4885RECQL 1140/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | USP2 1060/4885SMN1; SMN2 491/4885RECQL 2852/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | USP2 1275/4885SMN1; SMN2 1242/4885RECQL 1949/4885 |
| US-12577227-B2 | WDR5 inhibitors and modulators | WDR1, WDR5, WDR3 | USP2 2161/4885SMN1; SMN2 2571/4885RECQL 1493/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | USP2 4057/4885SMN1; SMN2 3901/4885RECQL 1351/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | USP2 2410/4885SMN1; SMN2 1972/4885RECQL 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.